Table 1.

Summary of liver monitoring requirements with tolcapone under prior and revised labeling

Prior label	Current label
(Tasmar prescribing information, 2005)	(Tasmar prescribing information, 2006)
(1999–2005)	(February 2006 and forward)
• ALT/AST levels should be determined	• ALT/AST levels should be determined
At baseline	At baseline
Every 2 weeks for the first year	Every 2–4 weeks for first 6 months
Every 4 weeks for the next 6 months	At intervals deemed clinically relevant thereafter
Every 8 weeks thereafter	• Discontinue tolcapone if AST or ALT exceeds 2 times the upper limit of normal
• Discontinue tolcapone if AST or ALT exceeds the upper limit of normal